Hemoglobin A1c Control, Part no. 220232 for use as quality control material to monitor the precision of laboratory testing procedures for HbA1c quantitation.
Publicado el 19 de diciembre de 2018 · Inicio del retiro: 5 de octubre de 2018
Resumen
FDA registra el retiro Z-0601-2019 de dispositivos médicos de Clase III, publicado el 19 de diciembre de 2018 e iniciado el 5 de octubre de 2018. Empresa responsable: Tosoh Bioscience Inc; Estado: Finalizado; Cantidad reportada: 1000; Lote: Lot 7055. La Clase III indica que no es probable que el producto cause consecuencias adversas para la salud.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Tosoh Bioscience has become aware of potential degradation of HbA1c control lot # 7055 before the 60-days product stability claim. If degradation of these controls occurs, P00 peaks may be seen and the % HbA1c control values may drift higher than the assigned range. This may result in delays when performing routine instrument quality control. If this issue occurs, there may be a delay in testing and reporting patient test results. Tosoh has received two (2) complaints related to this issue with no serious injuries reported.
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Tosoh Bioscience Inc
- Distribuidor
- Distributed nationwide. Foreign distribution to Canada.
- Lote
- Lot 7055
- Clasificación de riesgo
- Class III
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDAST AIA-Pack Testosterone, IN VITRO DIAGNOSTIC USE ONLY for the quantitative measurement of testosterone in22 de julio de 2026
- FDATosoh Bioscience AIA-PACK BHCG Calibration Verification Test Set-In Vitro Diagnostic for BHCG-pregnancy Part23 de septiembre de 2020
- FDAST AIA-PACK ACTH (ACTH: Adrenocorticotropic Hormone) is designed for IN VITRO DIAGNOSTIC USE ONLY for the2 de enero de 2019
- FDAAIA-PACK Folate (FOL) is designed for IN VITRO DIAGNOSTIC USE ONLY for the quantitative measurement of folate2 de enero de 2019
- FDAOrthopedic Salvage System (OSS) Porous Stem, Item No. 15039419 de diciembre de 2018
- FDABinding Site Human IgM Kit (for SPAPLUS), REF: NK012.S The device consists of reaction buffer, sheep anti-IgM19 de diciembre de 2018
Preguntas sobre este retiro
¿Hemoglobin A1c Control, Part no. 220232 for use as quality control material to monitor the precision of laboratory testing procedures for HbA1c quantitation. fue retirado del mercado?
Sí. FDA publicó el retiro Z-0601-2019 el 19 de diciembre de 2018. Peligro reportado: Tosoh Bioscience has become aware of potential degradation of HbA1c control lot # 7055 before the 60-days product stability claim. If degradation of these controls occurs, P00 peaks may be seen and the % HbA1c control values may drift higher than the assigned range. This may result in delays when performing routine instrument quality control. If this issue occurs, there may be a delay in testing and reporting patient test results. Tosoh has received two (2) complaints related to this issue with no serious injuries reported.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter